Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNMBiotechnology
-$0.39 today
- Market cap
- $326.66M
- Beta
- 0.89
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$1.57
Volume 0.20M
Average 0.26M
CTNM Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Contineum Therapeutics, Inc. Class A Common StockNASDAQ: CTNM
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 10.3% from a year ago
Cash & equivalents stood at $20.16M at the end of Q1 FY2026, down 10.3% from a year earlier and down 73.3% from the prior quarter. Over 3 fiscal years it compounded at +138.6% a year.
Context
- Cash & equivalents amounted to 7.7% of total assets at the end of Q1 FY2026, down 3.6 pp from a year earlier.
- Cash & equivalents increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -10.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 75.6M USD
- Year-over-year change
- +244.5%
- 4-year CAGR
- +101.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 75.6M | +244.5% |
| FY2024 | 2024-12-31 | 21.94M | +41.3% |
| FY2023 | 2023-12-31 | 15.53M | +178.8% |
| FY2022 | 2022-12-31 | 5.57M | +20.3% |
| FY2021 | 2021-12-31 | 4.63M | — |
Cash & Equivalents vs competitors
How CTNM compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -10.3% is the lowest of 8, against a peer median of +15.9%.
- Cash & equivalents amounts to 7.7% of total assets for CTNM, versus a peer median of 81.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $320.68M USD | +2154.3% | +126.9% | 81.5% |
| Mar 2026 | $263.76M USD | +64.1% | +54.0% | 95.5% | |
| Mar 2026 | $242.65M USD | -0.9% | +14.1% | 88.2% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $147.07M USD | +15.9% | -8.8% | 95.6% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $78.06M USD | +35.5% | +19.1% | 15.7% |
| Mar 2026 | $55.71M USD | +11.1% | +19.1% | 13.3% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $20.16M USD | -10.3% | +138.6% | 7.7% |
| Mar 2026 | CHF 19.17M CHF | -4.0% | -5.3% | 13.9% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding CTNM) | — | +15.9% | +19.1% | 81.5% | |
Competitors are the stored peer set for CTNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.63M | 5.57M | 15.53M | 21.94M | 75.6M |
| Short-term Investments | 64.37M | 41.67M | 109.66M | 182.82M | 187.29M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 775K | 1.15M | 2.52M | 1.63M | 5.02M |
| Total Current Assets | 69.78M | 48.39M | 127.71M | 206.39M | 267.92M |
| Property, Plant & Equipment (Net) | 642K | 2.12M | 1.4M | 6.46M | 8.47M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 97K | 129K | 1.28M | 3K | 256K |
| Total Non-current Assets | 739K | 2.24M | 2.68M | 6.46M | 8.73M |
| Total Assets | 70.52M | 50.64M | 130.39M | 212.85M | 276.64M |
| Account Payables | 660K | 430K | 635K | 1.81M | 1.02M |
| Short-term Debt | 1.25M | 3.95M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 79K | 1.31M | 2.48M | 3.37M | 1.59M |
| Total Current Liabilities | 3.67M | 7.55M | 5.48M | 9.97M | 9.74M |
| Long-term Debt | 3.66M | 0 | 192.62M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.6M | 3.03M | 110K | 0 | 0 |
| Total Non-current Liabilities | 5.26M | 3.82M | 192.84M | 4.81M | 5.91M |
| Total Liabilities | 8.93M | 11.37M | 198.32M | 14.78M | 15.65M |
| Common Stock | 12K | 12K | 2K | 26K | 37K |
| Retained Earnings | (73.61M) | (97.86M) | (75.14M) | (117.4M) | (177.38M) |
| Accumulated OCI | (35K) | (76K) | 108K | 71K | 260K |
| Other Stockholders Equity | (0) | (0) | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 61.59M | 39.27M | (67.94M) | 198.07M | 260.99M |
| Total Debt | 4.91M | 5.85M | 193.19M | 6.26M | 8.25M |
| Net Debt | 279K | 280K | 177.67M | (15.68M) | (67.35M) |
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
Intrinsic Alpha fair value
Locked
Current Price
$9.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.